|
gptkbp:instanceOf
|
gptkb:drug
opioid
|
|
gptkbp:abusePotential
|
high
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:N07BC02
|
|
gptkbp:brand
|
gptkb:Dolophine
gptkb:Methadose
Diskets
|
|
gptkbp:broadcastOn
|
gptkb:Schedule_II_(US)
|
|
gptkbp:CASNumber
|
gptkb:76-99-3
|
|
gptkbp:contraindication
|
acute asthma
paralytic ileus
severe respiratory depression
|
|
gptkbp:developedBy
|
gptkb:IG_Farben
1937
|
|
gptkbp:discoveredIn
|
gptkb:Germany
|
|
gptkbp:eliminationHalfLife
|
8-59 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:form
|
gptkb:tablet
gptkb:water
injectable
|
|
gptkbp:hasMolecularFormula
|
C21H27NO
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Methadone
|
|
gptkbp:interactsWith
|
gptkb:beer
gptkb:benzodiazepines
other CNS depressants
|
|
gptkbp:legalStatus
|
controlled substance
|
|
gptkbp:mechanismOfAction
|
NMDA receptor antagonist
mu-opioid receptor agonist
|
|
gptkbp:meltingPoint
|
235°C (hydrochloride salt)
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
309.45 g/mol
|
|
gptkbp:overdoseSymptoms
|
high
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
4095
DB00333
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
subcutaneous
intravenous
|
|
gptkbp:sideEffect
|
constipation
sweating
QT prolongation
drowsiness
respiratory depression
|
|
gptkbp:solubility
|
water soluble (hydrochloride salt)
|
|
gptkbp:synonym
|
6-(dimethylamino)-4,4-diphenylheptan-3-one
|
|
gptkbp:UNII
|
U76SF2399M
|
|
gptkbp:usedFor
|
pain management
opioid dependence treatment
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Opiate
|
|
gptkbp:bfsLayer
|
5
|